Rein Therapeutics Inc. (RNTX)
| Market Cap | 68.04M +145.6% |
| Revenue (ttm) | n/a |
| Net Income | -49.76M |
| EPS | -0.58 |
| Shares Out | 86.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 446,968 |
| Open | 0.8000 |
| Previous Close | 0.8250 |
| Day's Range | 0.7802 - 0.8169 |
| 52-Week Range | 0.6940 - 2.1800 |
| Beta | 1.36 |
| Analysts | Buy |
| Price Target | 6.00 (+660.75%) |
| Est. Earnings | Nov 13, 2026 |
About RNTX
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company’s lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company’s pipeline also includes preclinical programs ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for RNTX stock is "Buy." The 12-month stock price target is $6.0, which is an increase of 660.75% from the latest price.
News
Rein Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A novel IPF therapy, LTI-03, targets both lung scarring and regeneration by mimicking caveolin-1, showing strong anti-fibrotic effects and preservation of progenitor cells. Early clinical trials confirm safety and biomarker improvements, with a phase II trial underway and interim data expected soon.
Rein Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
A novel inhaled therapy for IPF, LTI-03, is advancing through a global phase II trial after resolving a temporary FDA hold. The drug’s dual mechanism—anti-fibrotic and epithelial cell preservation—sets it apart, with strong biomarker and safety data, robust funding, and regulatory support including orphan and fast track designations.
Rein Therapeutics Slides: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Rein Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 11, 2026.
Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress
AUSTIN, Texas, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and ...
Rein Therapeutics to Present at Upcoming September Investor Conferences
AUSTIN, Texas, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and ...
Rein Therapeutics granted Fast Track designation for LTI-03
Rein Therapeutics (RNTX) announced that the FDA has granted Fast Track designation to LTI-03 for the treatment of idiopathic pulmonary fibrosis.
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease progression Actively enrolling patients in the RENEW Phase 2 trial...
Rein Therapeutics Slides: Corporate presentation
Rein Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 19, 2026.
Rein Therapeutics Quarterly report: Q2 2026
Rein Therapeutics has published its Q2 2026 quarterly earnings report on August 14, 2026.
Rein Therapeutics Earnings release: Q2 2026
Rein Therapeutics released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
AUSTIN, Texas, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and f...
Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications
Data support ongoing Phase 2 “RENEW” trial First-in-human clinical study produced measurable reductions in multiple markers of lung scarring and inflammation in IPF patients Study confirms LTI-03 was ...
Rein Therapeutics announces RENEW clinical trial open for enrollment
Rein Therapeutics (RNTX) announced that its Phase 2 RENEW clinical trial is now open and enrolling patients across all five planned countries, with Germany joining the United States, United Kingdom,…
Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries
AUSTIN, Texas, July 21, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ: RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-cla...
Rein Therapeutics Transcript: AGM 2026
The meeting established a quorum and proceeded with votes on director elections, share authorization, auditor appointment, and executive compensation, all of which were approved. Final results will be filed in a Form 8-K within four business days.
Maxim starts Rein Therapeutics at Buy amid de-risked LTI-03 program
As previously reported, Maxim initiated coverage of Rein Therapeutics (RNTX) with a Buy rating and $4 price target The company has executed on several key milestones that have de-risked its…
Rein Therapeutics initiated with a Buy at Maxim
Maxim initiated coverage of Rein Therapeutics (RNTX) with a Buy rating and $4 price target
Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom
16 patients enrolled to date in trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) First patient randomized in the United Kingdom Clinical trial sites now actively enrolling in the United States, ...
Rein Therapeutics Proxy statement: Proxy filing
Rein Therapeutics filed a proxy statement on June 8, 2026, providing details for shareholder voting and corporate governance matters.
Rein Therapeutics Proxy statement: Proxy filing
Rein Therapeutics filed a proxy statement on June 8, 2026, providing details for shareholder voting and corporate governance matters.
Rein Therapeutics price target lowered to $8 from $10 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Rein Therapeutics (RNTX) to $8 from $10 and keeps a Buy rating on the shares post the Q1 report. The firm cites…
Rein Therapeutics Proxy statement: Proxy filing
Rein Therapeutics filed a proxy statement on May 28, 2026, providing details for shareholder voting and corporate governance matters.
Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
Total gross proceeds increased to $57.5 million Offering consisted solely of common stock Proceeds expected to fund Phase 2 trial of LTI-03 in IPF through completion and support operations into 2028 A...
Rein Therapeutics Quarterly report: Q1 2026
Rein Therapeutics has published its Q1 2026 quarterly earnings report on May 15, 2026.
Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock
AUSTIN, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ: RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-cl...